DelveInsight Business Research LLP

DelveInsight has launched a new report on “Hidradenitis Suppurativa – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Hidradenitis Suppurativa – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Hidradenitis Suppurativa Market Report:

1. The prevalence rate in the range of 0.2% to 4% is reported in epidemiology studies conducted for the US and Europe. Most studies, however, have mentioned limitations such as the likelihood of unreported mild cases and there is an estimated diagnostic delay of about 7 years. According to the DelveInsight analysis, when mild cases are also included, the total approximate prevalence of HS is 1% in the US. In the case of European epidemiology studies, similar findings were observed. Therefore, when mild cases are also included, the estimated prevalence, which is cited by most reports, is about 1%.

2. The diagnosed prevalent population of HS in seven major markets has been estimated to be around 1,230,513 for 2020, which is expected to rise by 2030 according to DelveInsight estimates. It is important to mention that most HS cases remain underdiagnosed for years.

Key benefits of the report:

1. Hidradenitis Suppurativa market report covers a descriptive overview and comprehensive insight of the Hidradenitis Suppurativa Epidemiology and Hidradenitis Suppurativa  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Hidradenitis Suppurativa market report provides insights on the current and emerging therapies.

3. Hidradenitis Suppurativa market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Hidradenitis Suppurativa market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hidradenitis Suppurativa market.

Got queries? Click here to know more about the Hidradenitis Suppurativa Market Landscape.

Hidradenitis Suppurativa Overview

Hidradenitis Suppurativa (HS) is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as Acne inversa and there is no biological or pathological test to facilitate diagnosis, it can be defined by its clinical features and its chronicity. 

Hidradenitis Suppurativa Market 

The dynamics of the Hidradenitis Suppurativa market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Novartis, InflaRx, ChemoCentryx, UCB Biopharma, Incyte Corporation, Janssen  Pharmaceutical/ Xbiotech, and others during the forecasted period 2018-2030.

Hidradenitis Suppurativa Pipeline Therapies and Key Companies 

1. IFX-1: InflaRx

2. Cosentyx/Secukinumab: Novartis

3. Avacopan: ChemoCentryx

4. Bimekizumab: UCB Biopharma

5. Bermekimab (MABp1): Janssen Pharmaceutica l / XBiotech

6. INCB054707: Incyte Corporation

Hidradenitis Suppurativa Market Drivers 

• Growing Patient Pool

• Increasing Awareness

• Improvement in Healthcare Economy and Affordable Treatment Options

• Improvement in the Diagnosis Rate

• Rich Emerging Pipeline

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Hidradenitis Suppurativa Patient Share (%) Overview at a Glance

5. Hidradenitis Suppurativa Market Overview at a Glance

6. Hidradenitis Suppurativa Disease Background and Overview

7. Hidradenitis Suppurativa Epidemiology and Patient Population

8. Country-Specific Patient Population of Hidradenitis Suppurativa 

9. Hidradenitis Suppurativa Current Treatment and Medical Practices

10. Unmet Needs

11. Hidradenitis Suppurativa Emerging Therapies

12. Hidradenitis Suppurativa Market Outlook

13. Country-Wise Hidradenitis Suppurativa Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Hidradenitis Suppurativa Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Hidradenitis Suppurativa Market Outlook 2030. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/